litlas
Log inCreate account

Thomas W. Flaig

Active 2006–2025

69
Papers
20,739
Citations
41
h-index
66
i10-index

Citations

Citations per year for Thomas W. Flaig1994: 3 citations2000: 1 citations2001: 1 citations2006: 1 citations2007: 9 citations2008: 5 citations2009: 11 citations2010: 11 citations2011: 37 citations2012: 75 citations2013: 219 citations2014: 238 citations2015: 242 citations2016: 237 citations2017: 219 citations2018: 243 citations2019: 744 citations2020: 763 citations2021: 825 citations2022: 569 citations2023: 481 citations2024: 878 citations2025: 356 citations2026: 16 citations1995–1999: no citations, so these years are not shown2002–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,003 citing papers, 25.4% of this breakdownChina: 653 citing papers, 8.3% of this breakdownUnited Kingdom: 533 citing papers, 6.8% of this breakdownItaly: 482 citing papers, 6.1% of this breakdownCanada: 439 citing papers, 5.6% of this breakdownGermany: 392 citing papers, 5% of this breakdownFrance: 360 citing papers, 4.6% of this breakdownSpain: 262 citing papers, 3.3% of this breakdownJapan: 249 citing papers, 3.2% of this breakdownNetherlands: 215 citing papers, 2.7% of this breakdownAustralia: 208 citing papers, 2.6% of this breakdownBelgium: 170 citing papers, 2.2% of this breakdown
0%25.4%Other 24.2%

Institutions

Fields

  • Medicine79.3%
  • Biochemistry, Genetics and Molecular Biology14.3%
  • Immunology and Microbiology2.7%
  • Computer Science0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Engineering0.4%
  • Other2%

Topics

  • Prostate Cancer Treatment and Research15.9%
  • Prostate Cancer Diagnosis and Treatment7.2%
  • Bladder and Urothelial Cancer Treatments7.1%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Radiopharmaceutical Chemistry and Applications3.9%
  • Urinary and Genital Oncology Studies3.8%
  • Other58%

Coauthors

All papers

Open in search
  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Authors: Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono - New England Journal of Medicine 2012 cited by 4,574

  2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Authors: Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 cited by 4,394

  3. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Authors: Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul N. Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, H. Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan J. Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 cited by 2,795

  4. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

    Authors: Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asım Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne‐Sophie Carret, Jonathan E. Rosenberg - Journal of Clinical Oncology 2022 cited by 267

  5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Authors: Charles J. Ryan, Matthew R. Smith, Karim Fizazi, Fred Saad, Peter F.A. Mulders, Cora N. Sternberg, Kurt Miller, Christopher J. Logothetis, Neal D. Shore, Eric J. Small, Joan Carles, Thomas W. Flaig, Mary-Ellen Taplin, Celestia S. Higano, Paul de Souza, Johann S. de Bono, Thomas W. Griffin, Peter De Porre, Margaret K. Yu, Youn C. Park, Jinhui Li, Thian Kheoh, Vahid Naini, Arturo Molina, Dana E. Rathkopf - The Lancet Oncology 2015 cited by 1,354

  6. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

    Authors: Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman‐Censits, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Vitaly Margulis, Omar Y. Mian, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Kyle A. Richards, Wade J. Sexton, Arlene O. Siefker‐Radtke, Matthew K. Tollefson, Jonathan D. Tward, Jonathan L. Wright, Mary A. Dwyer, Carly J. Cassara, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2022 cited by 302

  7. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    Authors: Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, Jamie Merchan, David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak - Journal of Clinical Oncology 2020 cited by 327

  8. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    Authors: Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Terence W. Friedlander, Rana R. McKay, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, J.P. Maroto Rey, Christiano Ferrario, Anne‐Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg - Journal of Clinical Oncology 2023 cited by 175

  9. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Authors: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498

  10. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology

    Authors: Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam S. Chang, Tracy M. Downs, Jason A. Efstathiou, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman‐Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker‐Radtke, Jonathan D. Tward, Jonathan L. Wright, Lisa A. Gurski, Alyse Johnson-Chilla - Journal of the National Comprehensive Cancer Network 2020 cited by 628

  11. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

    Authors: James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, A I Novikov, Philip W. Kantoff - Journal of Clinical Oncology 2019 cited by 278

  12. Bladder Cancer, Version 3.2024

    Authors: Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Mark K. Buyyounouski, Kevin Chan, Sam S. Chang, Paul Chang, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Harry W. Herr, Jean Hoffman‐Censits, Hristos Z. Kaimakliotis, Amar U. Kishan, Shilajit Kundu, Subodh M. Lele, Ronac Mamtani, Omar Y. Mian, Jeff M. Michalski, Jeffrey S. Montgomery, Mamta Parikh, Anthony Patterson, Charles C. Peyton, Elizabeth R. Plimack, Mark A. Preston, Kyle A. Richards, Wade J. Sexton, Arlene O. Siefker‐Radtke, Tyler F. Stewart, Debasish Sundi, Matthew K. Tollefson, Jonathan D. Tward, Jonathan L. Wright, Carly J. Cassara, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 cited by 236

  13. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

    Authors: Joshua J. Meeks, Hikmat Al‐Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff, Emil Christensen, Benjamin L. Woolbright, David J. McConkey, Lars Dyrskjøt - Nature Reviews Urology 2020 cited by 195

  14. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer

    Authors: Thomas W. Flaig, Michael Glodé, Daniel L. Gustafson, Adrie van Bokhoven, Yuzhen Tao, Shandra Wilson, Lih‐Jen Su, Yuan Li, Gail S. Harrison, Rajesh Agarwal, E. David Crawford, M. Scott Lucia, Michaël Pollak - The Prostate 2010 cited by 191

  15. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

    Authors: Thomas W. Flaig, Daniel L. Gustafson, Lih‐Jen Su, Joseph A. Zirrolli, Frances Crighton, Gail S. Harrison, A. Scott Pierson, Rajesh Agarwal, L. Michael Glodé - Investigational New Drugs 2006 cited by 317

  16. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

    Authors: Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, David C. Smith, Michael T. Schweizer, Mark N. Stein, Vasileios J. Assikis, Przemyslaw Twardowski, Thomas W. Flaig, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Ralph J. Hauke, Guru Sonpavde, Jorge A. García, Arif Hussain, Oliver Sartor, Shifeng Mao, Harry Cao, Wei Fu, Ting Wang, Rehab Abdallah, Su Jin Lim, Vanessa Bolejack, Channing J. Paller, Michael A. Carducci, Mark C. Markowski, Mario A. Eisenberger, Emmanuel S. Antonarakis - Journal of Clinical Oncology 2021 cited by 137

  17. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

    Authors: Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W. Flaig, Fábio Franke, Oscar B. Goodman, Stéphane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Daphne Wu, Kesav Yeruva, Peter De Porre, Sabine Brookman‐May, Susan Li, Jinhui Li, Shibu Thomas, Katherine B. Bevans, Suneel Mundle, Sharon McCarthy, Dana E. Rathkopf - The Lancet Oncology 2021 cited by 106

  18. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

    Authors: Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson - Clinical Cancer Research 2021 cited by 91

  19. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314

    Authors: Yi‐Tsung Lu, Melissa Plets, Gareth Morrison, Alexander Cunha, Steven Cen, Suhn K. Rhie, Kimberly D. Siegmund, Siamak Daneshmand, David I. Quinn, Joshua J. Meeks, Seth P. Lerner, Daniel P. Petrylak, David J. McConkey, Thomas W. Flaig, Ian M. Thompson, Amir Goldkorn - European Urology Oncology 2023 cited by 30

  20. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

    Authors: Ashish M. Kamat, Thomas W. Flaig, H. Barton Grossman, Badrinath R. Konety, Donald L. Lamm, Michael A. O’Donnell, Edward Uchio, Jason A. Efstathiou, John A. Taylor - Nature Reviews Urology 2015 cited by 246

  21. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

    Authors: Thomas W. Flaig, Maren Salzmann‐Sullivan, Lih‐Jen Su, Zhiyong Zhang, Molishree Joshi, Miguel A. Gijón, Jihye Kim, John J. Arcaroli, Adrie van Bokhoven, M. Scott Lucia, Francisco G. La Rosa, Isabel R. Schlaepfer - Oncotarget 2017 cited by 101

  22. Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

    Authors: Shilpa Gupta, Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes, Terence W. Friedlander, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Jaime R. Merchan, Scott T. Tagawa, Jason R. Brown, Yao Yu, Anne‐Sophie Carret, Heidi S. Wirtz, Maria Guseva, Blanca Homet Moreno, Matthew I. Milowsky - Journal of Clinical Oncology 2023 cited by 21

  23. KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer

    Authors: Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R Chandana, Ben Li, Joseph E. Burgents, Karim Fizazi - Future Oncology 2021 cited by 49

  24. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).

    Authors: Shilpa Gupta, Joaquim Bellmunt, Elizabeth R. Plimack, Guru Sonpavde, Petros Grivas, Andrea B. Apolo, Sumanta K. Pal, Arlene O. Siefker‐Radtke, Thomas W. Flaig, Matt D. Galsky, Jonathan E. Rosenberg, Platinum-Ineligibility in Bladder Cancer Working Group - Journal of Clinical Oncology 2022 cited by 41